Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Full details and steps to take here.

NKGN Insider Trading

Insider Ownership Percentage: 20.00%
Insider Buying (Last 12 Months): $1,261.12
Insider Selling (Last 12 Months): $0.00

NKGen Biotech Insider Trading History Chart

This chart shows the insider buying and selling history at NKGen Biotech by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

NKGen Biotech Share Price & Price History

Current Price: $0.80
Price Change: +0.30 (1.20%)
As of 02/29/2024 01:00 AM ET

This chart shows the closing price history over time for NKGN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Full details and steps to take here.

NKGen Biotech Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/6/2023Paul Y SongCEOBuy75$3.32$249.00171,045View SEC Filing Icon  
11/27/2023Paul Y SongCEOBuy244$2.88$702.72170,701View SEC Filing Icon  
11/21/2023Paul Y SongCEOBuy100$2.80$280.00170,405View SEC Filing Icon  
11/20/2023James A GrafCFOBuy10$2.94$29.4010View SEC Filing Icon  
See Full Table
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Learn more here.

SEC Filings (Institutional Ownership Changes) for NKGen Biotech (NYSE:NKGN)

28.50% of NKGen Biotech stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

NKGen Biotech Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/13/2024Northern Trust Corp15,722$43K0.0%N/A0.072%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
NKGen Biotech logo
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.
Read More on NKGen Biotech

Today's Range

Now: $0.80
Low: $0.80
High: $0.91

50 Day Range

MA: $2.13
Low: $0.80
High: $3.32

52 Week Range

Now: $0.80
Low: $0.80
High: $12.88

Volume

47,989 shs

Average Volume

38,196 shs

Market Capitalization

$17.45 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.38

Who are the company insiders with the largest holdings of NKGen Biotech?

NKGen Biotech's top insider shareholders include:
  1. Paul Y Song (CEO)
  2. James A Graf (CFO)
Learn More about top insider investors at NKGen Biotech.

Who are the major institutional investors of NKGen Biotech?

NKGen Biotech's top institutional investors include:
  1. Northern Trust Corp — 0.07%
Learn More about top institutional investors of NKGen Biotech stock.

Which major investors are buying NKGen Biotech stock?

During the previous quarter, NKGN stock was bought by institutional investors including:
  1. Northern Trust Corp
Within the previous year, these company insiders have bought NKGen Biotech stock:
  1. Paul Y Song (CEO)
  2. James A Graf (CFO)
Learn More investors buying NKGen Biotech stock.
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Full details and steps to take here.